Literature DB >> 24314801

A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.

Michael H Dahan1, Mohammed Agdi2, Fady Shehata2, Weonyoung Son2, Seang Lin Tan2.   

Abstract

OBJECTIVES: To compare rates of pregnancy and IVF parameters in subjects who were stimulated with FSH plus recombinant human luteinizing hormone or menopausal gonadotropins. To determine whether responses to type of LH differ in poor or good responders. STUDY
DESIGN: Retrospective analysis at a university-based fertility center. Subjects were women with good and poor ovarian reserve, who underwent in vitro fertilization during a 2 year period, as part of a long agonist (N=122), or microdose flair (N=79) protocol. Measurements included FSH and LH dose, number of oocytes collected, number of embryos obtained, and pregnancy and clinical pregnancy rates.
RESULTS: Patients treated with r-hLH (n=105) had higher numbers of eggs retrieved and of embryos while using less FSH than their hMG-treated (n=96) counterparts. Pregnancy and clinical pregnancy rates were significantly higher with r-hLH than with hMG protocols (p=0.008 and 0.009, respectively). If patients had a baseline serum FSH level ≥10IU/L, clinical pregnancy rates were higher when r-hLH was used. When the antral follicle count was below 6 no significant differences in stimulation parameters or outcomes were detected between the groups.
CONCLUSION: r-hLH may be beneficial when compared to hMG and used for in-vitro fertilization, except in subjects with baseline follicle counts less than 6. Further data should be obtained.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Human menopausal gonadotropins; IVF outcomes; Ovarian stimulation; Recombinant luteinizing hormone

Mesh:

Substances:

Year:  2013        PMID: 24314801     DOI: 10.1016/j.ejogrb.2013.10.027

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  11 in total

1.  Morbid obesity and pregnancy outcomes after single blastocyst transfer: a retrospective, North American study.

Authors:  Miguel Russo; Senem Ates; Talya Shaulov; Michael H Dahan
Journal:  J Assist Reprod Genet       Date:  2017-02-11       Impact factor: 3.412

2.  Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human menopausal gonadotropin in women with reduced ovarian reserve.

Authors:  Mario Mignini Renzini; Claudio Brigante; Giovanni Coticchio; Mariabeatrice Dal Canto; Ilaria Caliari; Ruggero Comi; Elena De Ponti; Rubens Fadini
Journal:  J Assist Reprod Genet       Date:  2017-09-04       Impact factor: 3.412

3.  Relationship between pre-ICSI meiotic spindle angle, ovarian reserve, gonadotropin stimulation, and pregnancy outcomes.

Authors:  Alina M Mahfoudh; Jeong H Moon; Sara Henderson; Elena Garcia-Cerrudo; Weon-Young Son; Michael H Dahan
Journal:  J Assist Reprod Genet       Date:  2017-02-28       Impact factor: 3.412

4.  A comparison of IVF outcomes transferring a single ideal blastocyst in women with polycystic ovary syndrome and normal ovulatory controls.

Authors:  Naama Steiner; Senem Ates; Talya Shaulov; Guy Shrem; Alexander Volodarsky-Perel; S Yehuda Dahan; Samer Tannus; Weon-Young Son; Michael H Dahan
Journal:  Arch Gynecol Obstet       Date:  2020-07-15       Impact factor: 2.344

5.  Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population.

Authors:  Alberto Revelli; Grazia Pettinau; Gemma Basso; Andrea Carosso; Alessandro Ferrero; Cecilia Dallan; Stefano Canosa; Gianluca Gennarelli; Daniela Guidetti; Claudia Filippini; Chiara Benedetto
Journal:  Reprod Biol Endocrinol       Date:  2015-07-25       Impact factor: 5.211

6.  Comparison between cycles of the same patients when using recombinant luteinizing hormone + recombinant follicle stimulating hormone (rFSH), human menopausal gonadotropin + rFSH and rFSH only.

Authors:  Ahter Tanay Tayyar; Semra Kahraman
Journal:  Arch Med Sci       Date:  2018-01-08       Impact factor: 3.318

Review 7.  Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review.

Authors:  Noemi Di Segni; Andrea Busnelli; Matteo Secchi; Federico Cirillo; Paolo Emanuele Levi-Setti
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-01       Impact factor: 6.055

8.  Influence of Maternal Age and Ovarian Reserve on the Decision to Continue or to Cancel IVF Cycles in Patients with One or Two Large Follicles: a Dual Effect.

Authors:  Guy Shrem; Mali Salmon-Divon; Alina M Mahfoudh; Jacques Balayla; Alexander Volodarsky-Perel; Sara Henderson; Atif Zeadna; Weon-Young Son; Naama Steiner; Michael H Dahan
Journal:  Reprod Sci       Date:  2021-06-11       Impact factor: 3.060

9.  A Comparison of Outcomes from In Vitro Fertilization Cycles Stimulated with Follicle Stimulating Hormone Plus either Recombinant Luteinizing Hormone or Human Menopausal Gonadotropins in Subjects Treated with Long Gonadotropin Releasing Hormone Agonist Protocols.

Authors:  Nathalie Bleau; Mohammed Agdi; WeonYoung Son; SeangLin Tan; Michael H Dahan
Journal:  Int J Fertil Steril       Date:  2017-02-16

10.  Histopathological profile of women who had previously failed in-vitro fertilization and the association to the outcome in the subsequent in-vitro fertilization cycle.

Authors:  Naama Steiner; Rola F Turki; Waleed El-Khayat; Ghada Al Malki; Samer Tannus; Michael H Dahan
Journal:  Obstet Gynecol Sci       Date:  2021-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.